Argenx Advances Combo Strategy in Myasthenia Gravis With New ADAPT Forward Study

Argenx (ARGX) announced an update on their ongoing clinical study.

ADAPT Forward 1 (NCT07284420) is a Phase 2a proof-of-concept study run by argenx to test whether adding a new drug, empasiprubart, to its approved therapy efgartigimod can help patients with generalized myasthenia gravis who only get a partial benefit from efgartigimod alone. The goal is to see if this combo can improve symptoms and quality of life while keeping side effects manageable, which would support a broader, longer-term strategy in autoimmune neurology.

The study tests two intravenous biologic drugs. Efgartigimod IV is argenx’s existing FcRn blocker already used to treat generalized myasthenia gravis. Empasiprubart IV is a newer biologic designed as an add-on treatment to further reduce disease activity in patients who still have significant symptoms, aiming to deepen clinical response beyond what efgartigimod provides on its own.

The trial is an interventional, single-arm Phase 2 study. All enrolled participants receive active treatment; there is no placebo or control group. Patients receive efgartigimod IV throughout the study, while eligible participants also receive empasiprubart IV in one part of the trial. There is no blinding, meaning both doctors and patients know which drugs are being given. The main purpose is to treat and to see early signals of safety and benefit rather than to provide definitive proof of efficacy.

The study is listed as recruiting, with argenx as the industry sponsor. The protocol was first submitted in December 2025, marking the formal launch of the trial setup. The most recent update was filed on January 9, 2026, signaling active study management and protocol refinement as sites open and patients enroll. Primary and final completion dates are still estimated, but these milestones will be key for when top-line data can be expected and when investors can look for a clearer readout on the combo strategy.

This update is relevant for investors because it shows argenx is trying to expand its myasthenia gravis franchise beyond efgartigimod monotherapy and defend its lead as competition builds in autoimmune neurology. Positive proof-of-concept data could support a deeper treatment option, justify premium pricing, and extend the product life cycle, which may support ARGX’s valuation. At the same time, the single-arm, open-label design means early results will be directional, not definitive, and markets may react cautiously until larger, controlled data arrive. Competing players in generalized myasthenia gravis and broader autoimmune markets will watch closely, as success here would reinforce argenx’s positioning in combination regimens and platform development.

The study is ongoing and recently updated, with further details available on the ClinicalTrials.gov portal.

To learn more about ARGX’s potential, visit the Argenx drug pipeline page.